Maillard reaction and immunogenicity of protein therapeutics

Figure 7 N^ε-(carboxymethyl)lysine (A) and 3DG-imidazolone (B) in interferon pharmaceuticals. Three vials of each drug were analyzed by competitive enzyme-linked immunosorbent assay in duplicates, and the pooled results were presented as mean ± SD. One μg-eq AGEs-BSA corresponds to the amount of CML or 3DG-imidazolone present in one microgram of the referent AGEs-BSA. The latter was prepared by incubating 10 mg/mL BSA with 0.5 mol/L glucose for 3 mo at 37 °C. AGEs: Advanced glycation endproducts; CML: N^ε-(carboxymethyl)lysine; BSA: Bovine serum albumin.